<DOC>
	<DOCNO>NCT02492490</DOCNO>
	<brief_summary>The objective trial determine autologous Stromal Vascular Fraction ( SVF ) derive Mesenchymal Stem Cell ( MSC ) infusion kidney transplantation Donation Citizen Death ( DCD ) effectively reduce need post transplant immunosuppressant elevate GFR allograft . The investigator infuse autologous SVF derive MSC recipient operation ass effect SVF derive MSC closely monitor renal function , dosage immunosuppressant , acute rejection , graft survival . 120 patient eligible study describe enrol , 60 patient intervention group 60 control group .</brief_summary>
	<brief_title>Effect SVF Derived MSC DCD Renal Transplantation</brief_title>
	<detailed_description>The objective trial determine autologous SVF derive MSC effectively reduce need post transplant immunosuppressant DCD kidney transplantation . Emphasis place safety autologous SVF derive MSC infusion , dosage immunosuppressant , GFR , percentage acute rejection . 120 patient eligible study describe enrol , 60 patient intervention group 60 control group . Kidneys donor DCD random allocate intervention group control group . In intervention group investigator collect SVF recipient special instrument transplantation , culture SVF abstain MSC . The abstained MSC infuse recipient DCD kidney transplantation operation 7 , 14 , 21 POD . The investigator assess whether induction therapy autologous SVF derive MSC feasible DCD kidney transplantation . The effectiveness autologous SVF derive MSC induction therapy reduce immunosuppressant , reduce rate rejection , elevate patient allograft survival , improve allograft function day 0 12 month transplantation . Additionally , investigator assess percentage acute rejection antibody mediate rejection Banff criterion , incidence delay graft function ( defined need post-transplant dialysis within one week ) , incidence adverse event include infection , grade 3 non-hematologic toxicity , grade 4 hematologic toxicity .</detailed_description>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Uremia patient race great equal 18 year age less 60 year old 2 . Patient willing receive kidney DCD 3 . Patient willing capable give write informed consent study participation able participate study 12 month 1 . Women pregnant , intend become pregnant next 1 year , breastfeeding , positive pregnancy test enrollment prior study medication administration 2 . Patient prior solid organ transplant cell transplant ( e.g . bone marrow islet cell ) . 3 . Patient deem likely second solid organ transplant cell transplant ( e.g . bone marrow islet cell ) next 3 year 4 . Patient receive concurrent SOT ( heart , liver , pancreas ) 5 . ABO incompatible donor recipient pair CDC crossmatch positive transplant 6 . Sensitized patient ( recent antiHLA Class I II Panel Reactive Antibodies ( PRA ) &gt; 10 % CDCassay ) patient identify high immunological risk transplant physician 7 . Donors recipient know hepatitis C antibodypositive polymerase chain reaction ( PCR ) positive hepatitis C 8 . Donors recipient know hepatitis B surface antigenpositive PCR positive hepatitis B 9 . Donors recipient know human immunodeficiency virus ( HIV ) infection 10 . Recipients risk tuberculosis ( TB ) Current clinical , radiographic laboratory evidence active latent TB determine local standard care History active TB : ( I ) . Within last 2 year , even treat ( II ) Greater 2 year ago , unless documentation adequate treatment accord locally accept clinical practice c. Recipients risk reactivation TB preclude administration conventional immunosuppressant ( determine investigator base upon appropriate evaluation ) 11 . Recipients significant infection contraindication would preclude transplant 12 . Recipients history hypercoagulable state 13 . Recipients history substance abuse ( drug alcohol ) within past 6 month , psychotic disorder capable adequate study followup . 14 . Recipients active peptic ulcer disease ( PUD ) , chronic diarrhea , gastrointestinal problem affect absorption 15 . Recipients history cancer within last 5 year ( exception : nonmelanoma skin cell cancer cure local resection permit ) 16 . Recipients chest radiograph ( 2 month prior randomization ) consistent acute lung parenchymal process malignancy 17 . Recipients hypersensitivity study drug 18 . Recipients use investigational drug within 30 day prior Day 1 visit 19 . Prisoner patient compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( e.g . infectious disease ) illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Kidney transplantation</keyword>
	<keyword>DCD</keyword>
	<keyword>Stromal Vascular Fraction</keyword>
	<keyword>MSC</keyword>
</DOC>